Visit us & discover the BEST brain molecular imaging for everyone at our booth #2127
MINDVIEW is the new business unit of Oncovision (1) for personalized molecular brain imaging and care. Its first product, CAREMIBRAIN, ULTRA-HIGH RESOLUTION dedicated brain PET, perfected since 2017, has proven clinical outcomes in MORE THAN 600 PATIENTS at leading hospitals in Spain, Germany and the United States (2), and FDA APPROVAL on late 2023.
ADVANCED, ACCESSIBLE and AFFORDABLE, Caremibrain is combining ultra-high resolution 1,5 mm, 12% sensitivity, powerful quantification / dynamic capabilities, award-winning patient experience, vastly reduced radiotracer dose and very short study time
Compact, light, energy-efficient, CMB is enabling access to the BEST brain PET that every person deserves, with unequalled productivity, ease of use, seamless multimodal integration and minimum initial and ongoing costs. Unprecedented screening, clinical diagnosis, therapy guidance, treatment results assessment, advanced neurological research and synergy imaging / tracer / therapy opportunities are possible now.
(1) Innovative company from Valencia, Spain, with proprietary technology and proven clinical outcomes in 100.000+ patients in radio-guided surgery, point of care scintigraphy and dedicated PET
(2) Including PET diagnosis vs clinical confirmation, improving brain condition diagnosis, type and stage of disease and correlation between different doctors vs whole body PET CT
Brands: CareMiBrain an ULTRA-HIGH RESOLUTION dedicated brain PET with extensive technical and clinical assessment and proven clinical outcomes in MORE THAN 600 PATIENTS at leading hospitals in Spain, Germany and US (FDA approval).